# UBS (Lux) Equity Fund – Health Care (USD)
| Most important figures |  |
| --- | --- |
|  | ISIN | 31.5.2021 | 30.11.2020 | 30.11.2019 |
| Net assets in USD |  | 108 229 803.03 | 146 733 995.43 | 156 984 287.60 |
| Class P-acc | LU0085953304 |  |  |  |
| Units outstanding |  | 220 118.7460 | 358 751.9580 | 438 503.7460 |
| Net asset value per unit in USD |  | 390.29 | 350.35 | 309.69 |
| Issue and redemption price per unit in USD 1 |  | 390.29 | 350.35 | 309.50 |
| Class Q-acc | LU0358044559 |  |  |  |
| Units outstanding |  | 93 831.8580 | 99 062.8980 | 113 972.6970 |
| Net asset value per unit in USD |  | 237.86 | 212.44 | 185.88 |
| Issue and redemption price per unit in USD 1 |  | 237.86 | 212.44 | 185.77 |
| 1  See note 1 |  |  |  |  |

UBS (Lux) Equity Fund – Health Care (USD) Semi-Annual Report as of 31 May 2021

## Structure of the Securities Portfolio
Geographical Breakdown as a % of net assets	
| United States | 61.10 |
| --- | --- |
| United Kingdom | 10.50 |
| Switzerland | 8.68 |
| Ireland | 5.92 |
| Japan | 3.99 |
| Denmark | 3.69 |
| Germany | 1.51 |
| New Zealand | 1.04 |
| China | 0.87 |
| Canada | 0.66 |
| Sweden | 0.66 |
| Hong Kong | 0.46 |
| Total | 99.08 |

Economic Breakdown as a % of net assets	
| Pharmaceuticals, cosmetics & medical products | 54.51 |
| --- | --- |
| Biotechnology | 16.33 |
| Healthcare & social services | 14.23 |
| Finance & holding companies | 9.53 |
| Chemicals | 2.88 |
| Internet, software & IT services | 1.60 |
| Total | 99.08 |


## Statement of Net Assets
Assets	31.5.2021
USD
Investments in securities, cost	80 383 106.26
| Investments in securities, unrealized appreciation (depreciation) | 	26 855 304.09	 |
| --- | --- |
| Total investments in securities (Note 1) | 107 238 410.35 |
| Cash at banks, deposits on demand and deposit accounts | 775 933.30 |
| Receivable on securities sales (Note 1) | 979 428.10 |
| Receivable on subscriptions | 346 517.95 |
| Interest receivable on liquid assets | 141.61 |
| Receivable on dividends | 158 842.66 |
| Other receivables | 97 500.37 |
| Total Assets | 109 596 774.34 |
|  |  |
| Liabilities |  |
| Payable on securities purchases (Note 1) | -732 475.31 |
| Payable on redemptions | -375 238.74 |
| Provisions for flat fee (Note 2) | -246 895.14 |
| Provisions for taxe d’abonnement (Note 3) | -9 068.74 |
| Provisions for other commissions and fees (Note 2) | 	-3 293.38	 |
| Total provisions | -259 257.26 |
| Total Liabilities | -1 366 971.31 |
|  |  |
| Net assets at the end of the period | 108 229 803.03 |
| Statement of Operations | USD |
| Income | 1.12.2020-31.5.2021 |
| Interest on liquid assets | 54.98 |
| Dividends | 799 463.48 |
| Income on securities lending (Note 11) | 28 117.22 |
| Other income (Note 1 a) | 1 287.37 |
| Total income | 828 923.05 |
|  |  |
| Expenses |  |
| Flat fee (Note 2) | -1 187 303.54 |
| Taxe d’abonnement (Note 3) | -28 835.92 |
| Cost on securities lending (Note 11) | -11 246.89 |
| Other commissions and fees (Note 2) | -3 201.43 |
| Interest on cash and bank overdraft | -140.37 |
| Total expenses | -1 230 728.15 |
|  |  |
| Net income (loss) on investments | -401 805.10 |
|  |  |
| Realized gain (loss) (Note 1) |  |
| Realized gain (loss) on market-priced securities without options | 19 930 842.05 |
| Realized gain (loss) on foreign exchange | 18 173.35 |
| Total realized gain (loss) | 19 949 015.40 |
|  |  |
| Net realized gain (loss) of the period | 19 547 210.30 |
|  |  |
| Changes in unrealized appreciation (depreciation) (Note 1) |  |
| Unrealized appreciation (depreciation) on market-priced securities without options | -5 554 645.90 |
| Total changes in unrealized appreciation (depreciation) | -5 554 645.90 |
|  |  |
| Net increase (decrease) in net assets as a result of operations | 13 992 564.40 |

UBS (Lux) Equity Fund – Health Care (USD) Semi-Annual Report as of 31 May 2021
| Statement of Changes in Net Assets |  |
| --- | --- |
|  | USD |
|  | 1.12.2020-31.5.2021 |
| Net assets at the beginning of the period | 146 733 995.43 |
| Subscriptions | 9 417 736.81 |
| Redemptions | 	-61 914 493.61	 |
| Total net subscriptions (redemptions) | -52 496 756.80 |
| Net income (loss) on investments | -401 805.10 |
| Total realized gain (loss) | 19 949 015.40 |
| Total changes in unrealized appreciation (depreciation) | 	-5 554 645.90	 |
| Net increase (decrease) in net assets as a result of operations | 13 992 564.40 |
| Net assets at the end of the period | 108 229 803.03 |
| Development of the outstanding units |  |
|  | 1.12.2020-31.5.2021 |
| Class | P-acc |
| Number of units outstanding at the beginning of the period | 358 751.9580 |
| Number of units issued | 20 935.4890 |
| Number of units redeemed | -159 568.7010 |
| Number of units outstanding at the end of the period | 220 118.7460 |
| Class | Q-acc |
| Number of units outstanding at the beginning of the period | 99 062.8980 |
| Number of units issued | 7 147.1470 |
| Number of units redeemed | -12 378.1870 |
| Number of units outstanding at the end of the period | 93 831.8580 |

UBS (Lux) Equity Fund – Health Care (USD) Semi-Annual Report as of 31 May 2021

## Statement of Investments in Securities and other Net Assets as of 31 May 2021
| Description | Quantity/ | Valuation in USD | as a % |
| --- | --- | --- | --- |
|  | Nominal | Unrealized gain | of net |
|  |  | (loss) on Futures/ | assets |
|  |  | Forward |  |
|  |  | Exchange Contracts/ |  |
|  |  | Swaps (Note 1) |  |
| Transferable securities and money market instruments listed on an official stock exchange |  |  |  |
| Bearer shares |  |  |  |
| Denmark |  |  |  |
| DKK	GENMAB AS DKK1 (BEARER) | 9 856.00 | 3 990 716.35 | 3.69 |
| Total Denmark |  | 3 990 716.35 | 3.69 |
| Hong Kong |  |  |  |
| HKD	ALIBABA HEALTH INF HKD0.01 | 200 000.00 | 496 308.61 | 0.46 |
| Total Hong Kong |  | 496 308.61 | 0.46 |
| Ireland |  |  |  |
| USD	ICON ORD EUR0.06 | 7 600.00 | 1 700 576.00 | 1.57 |
| Total Ireland |  | 1 700 576.00 | 1.57 |
| Japan |  |  |  |
| JPY	KISSEI PHARM CO NPV | 19 800.00 | 383 167.42 | 0.35 |
| Total Japan |  | 383 167.42 | 0.35 |
| New Zealand |  |  |  |
| NZD	FISHER & PAYKEL HE NPV | 52 121.00 | 1 130 354.38 | 1.04 |
| Total New Zealand |  | 1 130 354.38 | 1.04 |
| United Kingdom |  |  |  |
| GBP	ASTRAZENECA ORD USD0.25 | 53 434.00 | 6 111 454.44 | 5.65 |
| USD	LIVANOVA PLC ORD GBP1.00 (DI) | 26 100.00 | 2 180 394.00 | 2.01 |
| Total United Kingdom |  | 8 291 848.44 | 7.66 |
| United States |  |  |  |
| USD	ALNYLAM PHARMACEUTICALS INC COM | 6 247.00 | 887 011.53 | 0.82 |
| USD	BIO RAD LABS INC CL A | 4 917.00 | 2 961 853.29 | 2.74 |
| USD	BIOMARIN PHARMA COM USD0.001 | 16 000.00 | 1 236 800.00 | 1.14 |
| USD	BLUEPRINT MEDICINE COM USD0.001 | 4 584.00 | 418 748.40 | 0.39 |
| USD	DENALI THERAPEUTIC COM USD0.01 | 14 958.00 | 951 179.22 | 0.88 |
| USD	DEXCOM INC COM | 7 482.00 | 2 763 775.98 | 2.55 |
| USD	HILL-ROM HLDGS INC COM STK NPV | 20 784.00 | 2 312 843.52 | 2.14 |
| USD	INCYTE CORPORATION COM USD0.001 | 18 841.00 | 1 578 498.98 | 1.46 |
| USD	INTELLIA THERAPEUT COM USD0.0001 | 6 200.00 | 464 628.00 | 0.43 |
| USD	IRONWOOD PHARMACEU COM CL A USD0.001 | 97 872.00 | 1 132 379.04 | 1.05 |
| USD	MIRATI THERAPEUTIC COM NPV | 4 330.00 | 684 789.50 | 0.63 |
| USD	NATERA INC COM USD0.0001 | 16 951.00 | 1 595 767.14 | 1.47 |
| USD	SYNEOS HEALTH INC COM USD0.01 CL A | 18 200.00 | 1 599 780.00 | 1.48 |
| USD	VERTEX PHARMACEUTI COM USD0.01 | 9 850.00 | 2 055 005.50 | 1.90 |
| Total United States |  | 20 643 060.10 | 19.08 |
| Total Bearer shares |  | 36 636 031.30 | 33.85 |
| Registered shares |  |  |  |
| Canada |  |  |  |
| USD	ZYMEWORKS INC COM NPV	22 917.00 | 715 010.40 | 0.66 |
| Total Canada | 715 010.40 | 0.66 |
| China |  |  |  |  |
| HKD | HANGZHOU TIGERMED NPV | 45 500.00 | 945 022.10 | 0.87 |
| Total China | 945 022.10 | 0.87 |
| Ireland |  |  |  |  |
| USD | MEDTRONIC PLC USD0.0001 | 37 200.00 | 4 709 148.00 | 4.35 |
| Total Ireland	4 709 148.00	4.35 |
| Japan |  |  |  |  |
| JPY | TAKEDA PHARMACEUTI NPV | 115 800.00 | 3 936 744.82 | 3.64 |
| Total Japan |  | 3 936 744.82 | 3.64 |
| Switzerland |  |  |  |
| CHF	ALCON AG CHF0.04 | 53 784.00 | 3 741 287.64 | 3.46 |
| CHF	NOVARTIS AG CHF0.50(REGD) | 64 370.00 | 5 648 613.33 | 5.22 |
| Total Switzerland |  | 9 389 900.97 | 8.68 |
| United Kingdom |  |  |  |
| GBP	GLAXOSMITHKLINE ORD GBP0.25 | 160 778.00 | 3 072 114.36 | 2.84 |
| Total United Kingdom |  | 3 072 114.36 | 2.84 |
| United States |  |  |  |
| USD	ABBOTT LABS COM | 35 364.00 | 4 125 210.60 | 3.81 |
| USD	ABBVIE INC COM USD0.01 | 54 811.00 | 6 204 605.20 | 5.73 |
| USD	AMERICAN WELL CORP COM USD0.01 CL A | 53 653.00 | 667 979.85 | 0.62 |
| USD	AVANTOR INC COM USD0.01 | 97 050.00 | 3 120 157.50 | 2.88 |
| USD	CENTENE CORP DEL COM | 41 197.00 | 3 032 099.20 | 2.80 |
| USD	ELI LILLY AND CO COM NPV | 30 250.00 | 6 042 135.00 | 5.58 |
| USD	KARUNA THERAPEUTICS INC COM USD0.0001 | 4 717.00 | 527 454.94 | 0.49 |
| USD	LAB CORP AMER HLDG COM USD0.1 | 18 375.00 | 5 043 570.00 | 4.66 |

UBS (Lux) Equity Fund – Health Care (USD) Semi-Annual Report as of 31 May 2021
|  | Description | Quantity/ | Valuation in USD | as a % |
| --- | --- | --- | --- | --- |
|  | Nominal | Unrealized gain | of net |
|  |  | (loss) on Futures/ | assets |
|  |  | Forward |  |
|  |  | Exchange Contracts/ |  |
|  |  | Swaps (Note 1) |  |
|  |  |  |  |  |
| USD | MARAVAI LIFESCIENC USD0.01 A | 52 512.00 | 1 971 300.48 | 1.82 |
| USD | OPTION CARE HEALTH COM USD0.0001(POST REV SPLT) | 40 000.00 | 733 600.00 | 0.68 |
| USD | PRELUDE THERAPEUTI COM USD0.0001 | 16 879.00 | 586 714.04 | 0.54 |
| USD | PRIVIA HEALTH GROU USD0.01 | 17 229.00 | 563 905.17 | 0.52 |
| USD | SEAGEN INC COM USD0.001 | 12 850.00 | 1 996 247.50 | 1.85 |
| USD | SINGULAR GENOMICS COM USD0.0001 | 25 317.00 | 683 559.00 | 0.63 |
| USD | UNITEDHEALTH GRP COM USD0.01 | 24 726.00 | 10 185 133.92 | 9.41 |
| Total United States | 45 483 672.40 | 42.02 |
| Total Registered shares | 68 251 613.05 | 63.06 |
| Depository receipts |  |  |
| Germany |  |  |
| USD	BIONTECH SE SPON ADS EACH REP 1 ORD SHS	8 025.00 | 1 637 100.00 | 1.51 |
| Total Germany | 1 637 100.00 | 1.51 |
| Sweden |  |  |  |  |
| USD | OLINK HLDG AB ADS EACH REPR 1 ORD SH | 20 200.00 | 713 666.00 | 0.66 |
| Total Sweden | 713 666.00 | 0.66 |
| Total Depository receipts | 2 350 766.00 | 2.17 |
| Total Transferable securities and money market instruments listed on an official stock exchange | 107 238 410.35 | 99.08 |
| Total investments in securities | 107 238 410.35 | 99.08 |
|  |  |  |
| Cash at banks, deposits on demand and deposit accounts and other liquid assets | 775 933.30 | 0.72 |
| Other assets and liabilities | 215 459.38 | 0.20 |
| Total net assets | 108 229 803.03 | 100.00 |

UBS (Lux) Equity Fund – Health Care (USD) Semi-Annual Report as of 31 May 2021

Translation (ENDE, 2021-05-31):
# UBS (Lux) Equity Fund – Health Care (USD)
| Wichtigste Daten |  |
| --- | --- |
|  | ISIN | 31.5.2021 | 30.11.2020 | 30.11.2019 |
| Nettovermögen in USD |  | 108 229 803.03 | 146 733 995.43 | 156 984 287.60 |
| Klasse P-acc | LU0085953304 |  |  |  |
| Anteile im Umlauf |  | 220 118.7460 | 358 751.9580 | 438 503.7460 |
| Nettoinventarwert pro Anteil in USD |  | 390.29 | 350.35 | 309.69 |
| Ausgabe- und Rücknahmepreis pro Anteil in USD 1 |  | 390.29 | 350.35 | 309.50 |
| Klasse Q-acc | LU0358044559 |  |  |  |
| Anteile im Umlauf |  | 93 831.8580 | 99 062.8980 | 113 972.6970 |
| Nettoinventarwert pro Anteil in USD |  | 237.86 | 212.44 | 185.88 |
| Ausgabe- und Rücknahmepreis pro Anteil in USD 1 |  | 237.86 | 212.44 | 185.77 |
| 1  Siehe Erläuterung 1 |  |  |  |  |

UBS (Lux) Equity Fund – Health Care (USD) Halbjahresbericht per 31. Mai 2021

## Struktur des Wertpapierbestandes
Geographische Aufteilung in % des Nettovermögens	
| Vereinigte Staaten | 61.10 |
| --- | --- |
| Grossbritannien | 10.50 |
| Schweiz | 8.68 |
| Irland | 5.92 |
| Japan | 3.99 |
| Dänemark | 3.69 |
| Deutschland | 1.51 |
| Neuseeland | 1.04 |
| China | 0.87 |
| Kanada | 0.66 |
| Schweden | 0.66 |
| Hongkong | 0.46 |
| Total | 99.08 |

Wirtschaftliche Aufteilung in % des Nettovermögens	
| Pharmazeutik, Kosmetik & medizinische Produkte | 54.51 |
| --- | --- |
| Biotechnologie | 16.33 |
| Gesundheits- & Sozialwesen | 14.23 |
| Finanz- & Beteiligungsgesellschaften | 9.53 |
| Chemie | 2.88 |
| Internet, Software & IT-Dienste | 1.60 |
| Total | 99.08 |


## Nettovermögensaufstellung
Aktiva	31.5.2021
USD
Wertpapierbestand, Einstandswert	80 383 106.26
| Wertpapierbestand, nicht realisierte Werterhöhung (-minderung) | 	26 855 304.09	 |
| --- | --- |
| Total Wertpapierbestand (Erläuterung 1) | 107 238 410.35 |
| Bankguthaben, Sicht- und Fristgelder | 775 933.30 |
| Forderungen aus Wertpapierverkäufen (Erläuterung 1) | 979 428.10 |
| Forderungen aus Zeichnungen | 346 517.95 |
| Zinsforderungen aus liquiden Mitteln | 141.61 |
| Forderungen aus Dividenden | 158 842.66 |
| Andere Forderungen | 97 500.37 |
| Total Aktiva | 109 596 774.34 |
|  |  |
| Passiva |  |
| Verbindlichkeiten aus Wertpapierkäufen (Erläuterung 1) | -732 475.31 |
| Verbindlichkeiten aus Rücknahmen | -375 238.74 |
| Rückstellungen für Pauschale Verwaltungskommission (Erläuterung 2) | -246 895.14 |
| Rückstellungen für Abonnementsabgabe (Erläuterung 3) | -9 068.74 |
| Rückstellungen für andere Kommissionen und Gebühren (Erläuterung 2) | 	-3 293.38	 |
| Total Rückstellungen für Aufwendungen | -259 257.26 |
| Total Passiva | -1 366 971.31 |
|  |  |
| Nettovermögen am Ende der Berichtsperiode | 108 229 803.03 |
| Ertrags- und Aufwandsrechnung | USD |
| Erträge | 1.12.2020-31.5.2021 |
| Zinsertrag aus liquiden Mitteln | 54.98 |
| Dividenden | 799 463.48 |
| Erträge aus Securities Lending (Erläuterung 11) | 28 117.22 |
| Andere Erträge (Erläuterung 1 a) | 1 287.37 |
| Total Erträge | 828 923.05 |
|  |  |
| Aufwendungen |  |
| Pauschale Verwaltungskommission (Erläuterung 2) | -1 187 303.54 |
| Abonnementsabgabe (Erläuterung 3) | -28 835.92 |
| Kosten aus Securities Lending (Erläuterung 11) | -11 246.89 |
| Andere Kommissionen und Gebühren (Erläuterung 2) | -3 201.43 |
| Zinsaufwand aus liquiden Mitteln und Kontokorrentkredit | -140.37 |
| Total Aufwendungen | -1 230 728.15 |
|  |  |
| Nettoerträge (-verluste) aus Anlagen | -401 805.10 |
|  |  |
| Realisierte Gewinne (Verluste) (Erläuterung 1) |  |
| Realisierter Kursgewinn (-verlust) aus marktbewerteten Wertpapieren ausser Optionen | 19 930 842.05 |
| Realisierter Währungsgewinn (-verlust) | 18 173.35 |
| Total der realisierten Gewinne (Verluste) | 19 949 015.40 |
|  |  |
| Realisierter Nettogewinn (-verlust) der Berichtsperiode | 19 547 210.30 |
|  |  |
| Veränderungen der nicht realisierten Werterhöhung (-minderung) (Erläuterung 1) |  |
| Nicht realisierte Werterhöhung (-minderung) marktbewerteter Wertpapiere ausser Optionen | -5 554 645.90 |
| Total der Veränderungen der nicht realisierten Werterhöhung (-minderung) | -5 554 645.90 |
|  |  |
| Nettoerhöhung (-minderung) des Nettovermögens infolge Geschäftstätigkeit | 13 992 564.40 |

UBS (Lux) Equity Fund – Health Care (USD) Halbjahresbericht per 31. Mai 2021
| Veränderung des Nettovermögens |  |
| --- | --- |
|  | USD |
|  | 1.12.2020-31.5.2021 |
| Nettovermögen zu Beginn der Berichtsperiode | 146 733 995.43 |
| Zeichnungen | 9 417 736.81 |
| Rücknahmen | 	-61 914 493.61	 |
| Total Mittelzufluss (-abfluss) | -52 496 756.80 |
| Nettoerträge (-verluste) aus Anlagen | -401 805.10 |
| Total der realisierten Gewinne (Verluste) | 19 949 015.40 |
| Total der Veränderungen der nicht realisierten Werterhöhung (-minderung) | 	-5 554 645.90	 |
| Nettoerhöhung (-minderung) des Nettovermögens infolge Geschäftstätigkeit | 13 992 564.40 |
| Nettovermögen am Ende der Berichtsperiode | 108 229 803.03 |
| Entwicklung der Anteile im Umlauf |  |
|  | 1.12.2020-31.5.2021 |
| Klasse | P-acc |
| Anzahl der Anteile im Umlauf zu Beginn der Berichtsperiode | 358 751.9580 |
| Anzahl der ausgegebenen Anteile | 20 935.4890 |
| Anzahl der zurückgegebenen Anteile | -159 568.7010 |
| Anzahl der Anteile im Umlauf am Ende der Berichtsperiode | 220 118.7460 |
| Klasse | Q-acc |
| Anzahl der Anteile im Umlauf zu Beginn der Berichtsperiode | 99 062.8980 |
| Anzahl der ausgegebenen Anteile | 7 147.1470 |
| Anzahl der zurückgegebenen Anteile | -12 378.1870 |
| Anzahl der Anteile im Umlauf am Ende der Berichtsperiode | 93 831.8580 |

UBS (Lux) Equity Fund – Health Care (USD) Halbjahresbericht per 31. Mai 2021

## Aufstellung der Wertpapierbestände und anderer Nettovermögenswerte per 31. Mai 2021
| Bezeichnung | Anzahl/ | Bewertung in USD | in % des |
| --- | --- | --- | --- |
|  | Nominal | NR Kursgewinn | Netto- |
|  |  | (-verlust) auf Futures/ | vermögens |
|  |  | Devisentermin- |  |
|  |  | kontrakten/ |  |
|  |  | Swaps (Erl. 1) |  |
| Wertpapiere und Geldmarktinstrumente, die an einer offiziellen Börse gehandelt werden |  |  |  |
| Inhaberaktien |  |  |  |
| Dänemark |  |  |  |
| DKK	GENMAB AS DKK1 (BEARER) | 9 856.00 | 3 990 716.35 | 3.69 |
| Total Dänemark |  | 3 990 716.35 | 3.69 |
| Hongkong |  |  |  |
| HKD	ALIBABA HEALTH INF HKD0.01 | 200 000.00 | 496 308.61 | 0.46 |
| Total Hongkong |  | 496 308.61 | 0.46 |
| Irland |  |  |  |
| USD	ICON ORD EUR0.06 | 7 600.00 | 1 700 576.00 | 1.57 |
| Total Irland |  | 1 700 576.00 | 1.57 |
| Japan |  |  |  |
| JPY	KISSEI PHARM CO NPV | 19 800.00 | 383 167.42 | 0.35 |
| Total Japan |  | 383 167.42 | 0.35 |
| Neuseeland |  |  |  |
| NZD	FISHER & PAYKEL HE NPV | 52 121.00 | 1 130 354.38 | 1.04 |
| Total Neuseeland |  | 1 130 354.38 | 1.04 |
| Grossbritannien |  |  |  |
| GBP	ASTRAZENECA ORD USD0.25 | 53 434.00 | 6 111 454.44 | 5.65 |
| USD	LIVANOVA PLC ORD GBP1.00 (DI) | 26 100.00 | 2 180 394.00 | 2.01 |
| Total Grossbritannien |  | 8 291 848.44 | 7.66 |
| Vereinigte Staaten |  |  |  |
| USD	ALNYLAM PHARMACEUTICALS INC COM | 6 247.00 | 887 011.53 | 0.82 |
| USD	BIO RAD LABS INC CL A | 4 917.00 | 2 961 853.29 | 2.74 |
| USD	BIOMARIN PHARMA COM USD0.001 | 16 000.00 | 1 236 800.00 | 1.14 |
| USD	BLUEPRINT MEDICINE COM USD0.001 | 4 584.00 | 418 748.40 | 0.39 |
| USD	DENALI THERAPEUTIC COM USD0.01 | 14 958.00 | 951 179.22 | 0.88 |
| USD	DEXCOM INC COM | 7 482.00 | 2 763 775.98 | 2.55 |
| USD	HILL-ROM HLDGS INC COM STK NPV | 20 784.00 | 2 312 843.52 | 2.14 |
| USD	INCYTE CORPORATION COM USD0.001 | 18 841.00 | 1 578 498.98 | 1.46 |
| USD	INTELLIA THERAPEUT COM USD0.0001 | 6 200.00 | 464 628.00 | 0.43 |
| USD	IRONWOOD PHARMACEU COM CL A USD0.001 | 97 872.00 | 1 132 379.04 | 1.05 |
| USD	MIRATI THERAPEUTIC COM NPV | 4 330.00 | 684 789.50 | 0.63 |
| USD	NATERA INC COM USD0.0001 | 16 951.00 | 1 595 767.14 | 1.47 |
| USD	SYNEOS HEALTH INC COM USD0.01 CL A | 18 200.00 | 1 599 780.00 | 1.48 |
| USD	VERTEX PHARMACEUTI COM USD0.01 | 9 850.00 | 2 055 005.50 | 1.90 |
| Total Vereinigte Staaten |  | 20 643 060.10 | 19.08 |
| Total Inhaberaktien |  | 36 636 031.30 | 33.85 |
| Namensaktien |  |  |  |
| Kanada |  |  |  |
| USD	ZYMEWORKS INC COM NPV	22 917.00 | 715 010.40 | 0.66 |
| Total Kanada | 715 010.40 | 0.66 |
| China |  |  |  |  |
| HKD | HANGZHOU TIGERMED NPV | 45 500.00 | 945 022.10 | 0.87 |
| Total China | 945 022.10 | 0.87 |
| Irland |  |  |  |  |
| USD | MEDTRONIC PLC USD0.0001 | 37 200.00 | 4 709 148.00 | 4.35 |
| Total Irland | 4 709 148.00 | 4.35 |
| Japan |  |  |  |  |
| JPY | TAKEDA PHARMACEUTI NPV | 115 800.00 | 3 936 744.82 | 3.64 |
| Total Japan | 3 936 744.82 | 3.64 |
| Schweiz |  |  |  |  |
| CHF | ALCON AG CHF0.04 | 53 784.00 | 3 741 287.64 | 3.46 |
| CHF | NOVARTIS AG CHF0.50(REGD) | 64 370.00 | 5 648 613.33 | 5.22 |
| Total Schweiz |  | 9 389 900.97 | 8.68 |
| Grossbritannien |  |  |  |
| GBP	GLAXOSMITHKLINE ORD GBP0.25 | 160 778.00 | 3 072 114.36 | 2.84 |
| Total Grossbritannien |  | 3 072 114.36 | 2.84 |
| Vereinigte Staaten |  |  |  |
| USD	ABBOTT LABS COM | 35 364.00 | 4 125 210.60 | 3.81 |
| USD	ABBVIE INC COM USD0.01 | 54 811.00 | 6 204 605.20 | 5.73 |
| USD	AMERICAN WELL CORP COM USD0.01 CL A | 53 653.00 | 667 979.85 | 0.62 |
| USD	AVANTOR INC COM USD0.01 | 97 050.00 | 3 120 157.50 | 2.88 |
| USD	CENTENE CORP DEL COM | 41 197.00 | 3 032 099.20 | 2.80 |
| USD	ELI LILLY AND CO COM NPV | 30 250.00 | 6 042 135.00 | 5.58 |
| USD	KARUNA THERAPEUTICS INC COM USD0.0001 | 4 717.00 | 527 454.94 | 0.49 |
| USD	LAB CORP AMER HLDG COM USD0.1 | 18 375.00 | 5 043 570.00 | 4.66 |

UBS (Lux) Equity Fund – Health Care (USD) Halbjahresbericht per 31. Mai 2021
|  | Bezeichnung | Anzahl/ | Bewertung in USD | in % des |
| --- | --- | --- | --- | --- |
|  | Nominal | NR Kursgewinn | Netto- |
|  |  | (-verlust) auf Futures/ | vermögens |
|  |  | Devisentermin- |  |
|  |  | kontrakten/ |  |
|  |  | Swaps (Erl. 1) |  |
|  |  |  |  |  |
| USD | MARAVAI LIFESCIENC USD0.01 A | 52 512.00 | 1 971 300.48 | 1.82 |
| USD | OPTION CARE HEALTH COM USD0.0001(POST REV SPLT) | 40 000.00 | 733 600.00 | 0.68 |
| USD | PRELUDE THERAPEUTI COM USD0.0001 | 16 879.00 | 586 714.04 | 0.54 |
| USD | PRIVIA HEALTH GROU USD0.01 | 17 229.00 | 563 905.17 | 0.52 |
| USD | SEAGEN INC COM USD0.001 | 12 850.00 | 1 996 247.50 | 1.85 |
| USD | SINGULAR GENOMICS COM USD0.0001 | 25 317.00 | 683 559.00 | 0.63 |
| USD | UNITEDHEALTH GRP COM USD0.01 | 24 726.00 | 10 185 133.92 | 9.41 |
| Total Vereinigte Staaten |  | 45 483 672.40 | 42.02 |
| Total Namensaktien |  | 68 251 613.05 | 63.06 |
| Depository Receipts |  |  |  |
| Deutschland |  |  |  |
| USD	BIONTECH SE SPON ADS EACH REP 1 ORD SHS | 8 025.00 | 1 637 100.00 | 1.51 |
| Total Deutschland |  | 1 637 100.00 | 1.51 |
| Schweden |  |  |  |
| USD	OLINK HLDG AB ADS EACH REPR 1 ORD SH | 20 200.00 | 713 666.00 | 0.66 |
| Total Schweden |  | 713 666.00 | 0.66 |
| Total Depository Receipts |  | 2 350 766.00 | 2.17 |
| Total Wertpapiere und Geldmarktinstrumente, die an einer offiziellen Börse gehandelt werden |  | 107 238 410.35 | 99.08 |
| Total des Wertpapierbestandes |  | 107 238 410.35 | 99.08 |
|  |  |  |  |
| Bankguthaben, Sicht- und Fristgelder und andere liquide Mittel |  | 775 933.30 | 0.72 |
| Andere Aktiva und Passiva |  | 215 459.38 | 0.20 |
| Total des Nettovermögens |  | 108 229 803.03 | 100.00 |

UBS (Lux) Equity Fund – Health Care (USD) Halbjahresbericht per 31. Mai 2021